Related Experiment Video
Updated: Jan 8, 2026
Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome
Published on: April 25, 2025
Treatment of Advanced Prostate Cancer
Min Yuen Teo1, Dana E Rathkopf1, Philip Kantoff1
1Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA;
Abstract:
The therapeutic landscape of prostate cancer has been transformed over the last decade by new therapeutics, advanced functional imaging, next-generation sequencing, and better use of existing therapies in early-stage disease. Until 2004, progression on androgen deprivation therapy for metastatic disease was treated with the addition of secondary hormonal manipulation; in the last decade, six systemic agents have been approved for the treatment of castration-resistant prostate cancer. We review clinical trials and survival benefit for these therapies and assess how the understanding of the disease shifted as these therapies were developed. We also discuss advances in noncastrate disease states, identification of biomarkers for prognosis and treatment selection, and opportunities in locoregional therapy to delay androgen deprivation therapy.
Insights
The prostate cancer treatment landscape has significantly advanced with new therapies and diagnostic tools. Recent approvals offer improved outcomes for castration-resistant prostate cancer, transforming patient care.
Area of Science:
- Oncology
- Medical Therapeutics
- Cancer Diagnostics
Background:
- Prostate cancer treatment has evolved significantly over the past decade.
- Traditional treatment for metastatic disease progression involved secondary hormonal manipulation.
- The last ten years have seen the approval of six new systemic agents for castration-resistant prostate cancer.
Purpose of the Study:
- To review the clinical trials and survival benefits of newly approved therapies for prostate cancer.
- To assess the paradigm shift in understanding prostate cancer driven by therapeutic advancements.
- To discuss progress in noncastrate disease management, biomarker identification, and locoregional therapy.
Main Methods:
- Review of clinical trials data for systemic agents in castration-resistant prostate cancer.
- Analysis of survival benefits associated with new therapeutic options.
- Assessment of advancements in functional imaging and next-generation sequencing.
- Evaluation of strategies for noncastrate disease states and locoregional therapies.
Main Results:
- Six systemic agents have been approved for castration-resistant prostate cancer in the last decade.
- These new therapies represent a significant transformation in managing advanced prostate cancer.
- Advances in imaging and sequencing aid in early-stage disease management and biomarker discovery.
Conclusions:
- The therapeutic landscape for prostate cancer has been revolutionized by novel systemic agents and improved diagnostics.
- Understanding of prostate cancer has shifted, leading to more personalized and effective treatment strategies.
- Future directions include optimizing locoregional therapies and leveraging biomarkers for treatment selection.
Related Concept Videos
05:12Murine Nasal Lavage Fluid Collection without Blood Contamination
03:40Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome
04:35Saline Lavage for Sampling of the Canine Nasal Immune Microenvironment
08:47Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
07:15Intranasal Administration of CNS Therapeutics to Awake Mice